The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study |
| |
Authors: | Umit Dundar Vural Kavuncu Ihsan H Ciftci Deniz Evcik Ozlem Solak Tuncay Cakir |
| |
Institution: | (1) Department of Physical Medicine and Rehabilitation, Afyon Kocatepe University Faculty of Medicine, Mavi Hastane, 03200 Afyonkarahisar, Turkey;(2) Microbiology and Clinical Microbiology, Kocatepe University Faculty of Medicine, Afyonkarahisar, Turkey;(3) Physical Medicine and Rehabilitation, Ufuk University Faculty of Medicine, Ankara, Turkey |
| |
Abstract: | There is much evidence suggesting that the decline in ovarian function after menopause is associated with spontaneous increases
in proinflammatory cytokines. Treatment with risedronate is accompanied by significant changes in bone turnover and bone mineral
density. The objective of this study was to determine the effects of risedronate treatment on the level of serum cytokines
including receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin among postmenopausal women with osteoporosis.
The study group consisted of 61 postmenopausal women with osteoporosis. Patients were randomly divided in two groups: In group
1 (n = 41) postmenopausal women received oral risedronate (35 mg/week), calcium (1,000 mg/day), and vitamin D (400 IU/day) for
12 months. In group 2 (control group; n = 20) patients received only oral calcium (1,000 mg/day) and vitamin D (400 IU/day). Bone mineral density (BMD) of lumbar
spine (L1–L4) and proximal femur were determined using dual X-ray absorptiometry at baseline and after one year. Venous blood
samples were obtained for determination of serum cytokines including interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α),
RANKL, osteoprotegerin, and markers of bone formation and resorption. Levels of serum cytokines were measured before therapy
and after three and 6 months. Markers of bone metabolism were studied before therapy and after 6 months. In group 1 (risedronate
plus calcium/vitamin D-treated patients), serum levels of RANKL and IL-1β significantly decreased and the level of osteoprotegerin
significantly increased after three and 6 months, but no significant difference was found in TNF-α level. In group 2, however,
the level of serum cytokines did not change after three and 6 months. In cases of bone turnover, both markers of bone resorption
and formation significantly decreased after 6 months in group 1. In conclusion risedronate could improve osteoporosis by increasing
osteoprotegerin and reducing RANKL and IL-1β. |
| |
Keywords: | Osteoporosis Risedronate RANKL Osteoprotegerin IL-1β |
本文献已被 SpringerLink 等数据库收录! |
|